JP6713483B2 - ミューオピオイド受容体アンタゴニストとオピオイド剤との組み合わせ剤形 - Google Patents

ミューオピオイド受容体アンタゴニストとオピオイド剤との組み合わせ剤形 Download PDF

Info

Publication number
JP6713483B2
JP6713483B2 JP2017550832A JP2017550832A JP6713483B2 JP 6713483 B2 JP6713483 B2 JP 6713483B2 JP 2017550832 A JP2017550832 A JP 2017550832A JP 2017550832 A JP2017550832 A JP 2017550832A JP 6713483 B2 JP6713483 B2 JP 6713483B2
Authority
JP
Japan
Prior art keywords
weight
sulfate
opioid
formulation
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017550832A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018513138A (ja
JP2018513138A5 (enExample
Inventor
シャオリン リー，
シャオリン リー，
マンシュウ レオン，
マンシュウ レオン，
ハオ チャン，
ハオ チャン，
ベンカット アール． サラディ，
ベンカット アール． サラディ，
ユン モー，
ユン モー，
Original Assignee
セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー
セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー, セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー filed Critical セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー
Publication of JP2018513138A publication Critical patent/JP2018513138A/ja
Publication of JP2018513138A5 publication Critical patent/JP2018513138A5/ja
Application granted granted Critical
Publication of JP6713483B2 publication Critical patent/JP6713483B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2017550832A 2015-04-02 2016-03-31 ミューオピオイド受容体アンタゴニストとオピオイド剤との組み合わせ剤形 Active JP6713483B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562141981P 2015-04-02 2015-04-02
US62/141,981 2015-04-02
PCT/US2016/025176 WO2016161069A1 (en) 2015-04-02 2016-03-31 Combination dosage form of a mu opioid receptor antagonist and an opioid agent

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020016858A Division JP2020073583A (ja) 2015-04-02 2020-02-04 ミューオピオイド受容体アンタゴニストとオピオイド剤との組み合わせ剤形

Publications (3)

Publication Number Publication Date
JP2018513138A JP2018513138A (ja) 2018-05-24
JP2018513138A5 JP2018513138A5 (enExample) 2019-03-14
JP6713483B2 true JP6713483B2 (ja) 2020-06-24

Family

ID=55806767

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017550832A Active JP6713483B2 (ja) 2015-04-02 2016-03-31 ミューオピオイド受容体アンタゴニストとオピオイド剤との組み合わせ剤形
JP2020016858A Withdrawn JP2020073583A (ja) 2015-04-02 2020-02-04 ミューオピオイド受容体アンタゴニストとオピオイド剤との組み合わせ剤形

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020016858A Withdrawn JP2020073583A (ja) 2015-04-02 2020-02-04 ミューオピオイド受容体アンタゴニストとオピオイド剤との組み合わせ剤形

Country Status (27)

Country Link
US (4) US20160287573A1 (enExample)
EP (1) EP3277278B1 (enExample)
JP (2) JP6713483B2 (enExample)
KR (1) KR20170132325A (enExample)
CN (1) CN107820424B (enExample)
AU (1) AU2016243691A1 (enExample)
BR (1) BR112017021120A2 (enExample)
CA (1) CA2980328A1 (enExample)
CY (1) CY1122828T1 (enExample)
DK (1) DK3277278T3 (enExample)
ES (1) ES2774473T3 (enExample)
HK (1) HK1247105A1 (enExample)
HR (1) HRP20200432T1 (enExample)
HU (1) HUE048785T2 (enExample)
IL (1) IL254593A0 (enExample)
LT (1) LT3277278T (enExample)
ME (1) ME03671B (enExample)
MX (1) MX2017012474A (enExample)
PH (1) PH12017501767A1 (enExample)
PL (1) PL3277278T3 (enExample)
PT (1) PT3277278T (enExample)
RS (1) RS60074B1 (enExample)
RU (1) RU2017134794A (enExample)
SI (1) SI3277278T1 (enExample)
SM (1) SMT202000157T1 (enExample)
TW (1) TW201642856A (enExample)
WO (1) WO2016161069A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3277278B1 (en) 2015-04-02 2020-01-08 Theravance Biopharma R&D IP, LLC Combination dosage form of a mu opioid receptor antagonist and an opioid agent
WO2019031560A1 (ja) * 2017-08-08 2019-02-14 日本合成化学工業株式会社 医薬錠剤、およびその製造方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2412409T3 (es) 1997-12-22 2013-07-11 Euro-Celtique S.A. Forma farmacéutica para dosificación oral que comprende una combinación de un agonista opiáceo y un antagonista opiáceo
US6419960B1 (en) 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US6451806B2 (en) 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
AR029538A1 (es) * 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
US7842307B2 (en) 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
DK1414451T3 (da) * 2001-08-06 2009-08-10 Euro Celtique Sa Opioidagonistformuleringer med frigivelig og sekvenstreret antagonist
AU2003301121A1 (en) * 2002-12-18 2004-07-14 Pain Therapeutics, Inc. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
US20050013863A1 (en) 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
AU2004314693B2 (en) 2003-09-26 2011-04-07 Alza Corporation Drug coating providing high drug loading and methods for providing the same
TWI415635B (zh) 2004-05-28 2013-11-21 必治妥施貴寶公司 加衣錠片調製物及製備彼之方法
AU2006218603A1 (en) * 2005-03-02 2006-09-08 Theravance, Inc. Quinolinone compounds as 5-HT4 receptor agonists
MY145633A (en) 2006-03-01 2012-03-15 Theravance Inc 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
CN101395154B (zh) * 2006-03-01 2011-01-19 施万制药 作为μ阿片受体拮抗剂的8-氮杂双环[3.2.1]辛烷化合物
CN101500542A (zh) * 2006-07-11 2009-08-05 共有药物有限公司 控释制剂
TWI409067B (zh) 2007-02-28 2013-09-21 Theravance Inc ８-氮雜雙環〔３．２．１〕辛烷化合物之結晶型
TWI415850B (zh) 2007-07-20 2013-11-21 Theravance Inc 製備ｍｕ類鴉片受體拮抗劑之中間物的方法
AU2009244190B2 (en) * 2008-05-07 2016-02-25 Salix Pharmaceuticals, Ltd. Methods of treating bowel disease by administering a bowel cleanser and an antibiotic
EP2210595A1 (en) 2009-01-14 2010-07-28 LEK Pharmaceuticals d.d. Active coating of pharmaceutical dosage forms
MX2011011919A (es) * 2009-05-12 2012-01-27 Bpsi Holdings Llc Sistemas de recubrimiento de pelicula de liberacion inmediata con barrera contra humedad mejorada y sustratos recubiertos con dichos sistemas.
IT1398930B1 (it) * 2010-03-24 2013-03-28 Molteni & C Formulazioni farmaceutiche bistrato contenenti agonisti ed antagonisti oppioidi.
AU2011295837B2 (en) * 2010-09-03 2015-06-18 Astrazeneca Uk Limited Drug formulations using water soluble antioxidants
ES2801725T3 (es) 2011-02-01 2021-01-12 Bristol Myers Squibb Co Formulaciones farmacéuticas que incluyen un compuesto de amina
US9339489B2 (en) * 2013-03-15 2016-05-17 Aprecia Pharmaceuticals Company Rapid disperse dosage form containing levetiracetam
EP3277278B1 (en) 2015-04-02 2020-01-08 Theravance Biopharma R&D IP, LLC Combination dosage form of a mu opioid receptor antagonist and an opioid agent

Also Published As

Publication number Publication date
HRP20200432T1 (hr) 2020-06-12
SMT202000157T1 (it) 2020-05-08
RS60074B1 (sr) 2020-05-29
SI3277278T1 (sl) 2020-04-30
US20180050028A1 (en) 2018-02-22
US20210161884A1 (en) 2021-06-03
US11452723B2 (en) 2022-09-27
IL254593A0 (en) 2017-11-30
HK1247105A1 (zh) 2018-09-21
DK3277278T3 (da) 2020-04-06
EP3277278B1 (en) 2020-01-08
KR20170132325A (ko) 2017-12-01
ES2774473T3 (es) 2020-07-21
HUE048785T2 (hu) 2020-08-28
ME03671B (me) 2020-10-20
US10369142B2 (en) 2019-08-06
PT3277278T (pt) 2020-04-16
WO2016161069A1 (en) 2016-10-06
CY1122828T1 (el) 2021-05-05
TW201642856A (zh) 2016-12-16
US10946009B2 (en) 2021-03-16
EP3277278A1 (en) 2018-02-07
JP2018513138A (ja) 2018-05-24
US20160287573A1 (en) 2016-10-06
MX2017012474A (es) 2018-01-11
RU2017134794A (ru) 2019-04-04
US20190321350A1 (en) 2019-10-24
CN107820424A (zh) 2018-03-20
LT3277278T (lt) 2020-03-25
BR112017021120A2 (pt) 2018-07-03
JP2020073583A (ja) 2020-05-14
PH12017501767A1 (en) 2018-06-11
CA2980328A1 (en) 2016-10-06
PL3277278T3 (pl) 2020-07-27
AU2016243691A1 (en) 2017-10-12
CN107820424B (zh) 2020-07-28

Similar Documents

Publication Publication Date Title
EP0888111B1 (en) Modified release multiple-units dosage composition
CZ284382B6 (cs) Pevná léková forma s řízeným uvolňováním účinné látky
HUP0000138A2 (hu) Szabályozott hatóanyag-leadású opioid analgetikumokat tartalmazó gyógyászati készítmények
WO2010127345A2 (en) Orally disintegrating tablet compositions comprising combinations of high and low-dose drugs
WO2013092589A1 (en) Multiple unit pellet tablet formulation comprising an opioid
US11452723B2 (en) Combination dosage form of a mu opioid receptor antagonist and an opioid agent
US20100010029A1 (en) Acute Pain Medications Based on Fast Acting Diclofenac-Opioid Combinations
US20080118554A1 (en) Pharmaceutical compositions comprising a combination of piperidinoalkanol and decongestant
JP2023510965A (ja) メトトレキサート投薬形態
AU2020233614B2 (en) Dosage form providing prolonged release of tapentadol phosphoric acid salt
US20120082718A1 (en) Morphine Formulations
US12303604B1 (en) Pharmaceutical formulations comprising naltrexone and/or bupropion
US20080193537A1 (en) Morphine Sulfate Formulations
US20080014261A1 (en) Non-narcotic biphasic release compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction
US20080008772A1 (en) Narcotic biphasic release compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction
WO2021220133A1 (en) Novel multiparticulate pharmaceutical composition of tamsulosin and solifenacin
AU2021201351B1 (en) Dosage form providing prolonged release of a salt of Tapentadol with L-(+)-tartaric acid
US20090162431A1 (en) Sustained release formulations containing acetaminophen and tramadol

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191129

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20191129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200204

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200518

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200603

R150 Certificate of patent or registration of utility model

Ref document number: 6713483

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250